Gamida Cell, a leader in adult stem cell expansion technologies and
products, announced today that it has completed enrollment for a Phase
I/II clinical trial of NiCord, the company’s second pipeline product.
NiCord is in development as an experimental treatment for a series of
indications that potentially could be cured with a bone marrow
transplantation including hematological malignancies (blood cancer),
sickle cell disease, thalassemia, severe autoimmune diseases and
metabolic diseases. The clinical trial announced today
(clinicaltrials.gov identifier NCT01221857) is studying NiCord as an
alternative investigational treatment for hematological malignancies
(HM). A combined total of 11 patients were transplanted at Duke
University Medical Center and at Loyola University Medical Center. Dr.
Mitchell E. Horwitz of Duke University Medical Center is the principal
investigator. Final results of the Phase I/II study are expected within
6 months. The company is also actively enrolling for a Phase I/II study
of NiCord as an experimental treatment for sickle cell, a genetic blood
disease (clinicaltrials.gov identifier NCT01590628).
NiCord is an expanded cell graft derived from an entire unit of
umbilical cord blood enriched with stem cells. NiCord was developed
based on Gamida Cell’s proprietary NAM technology. As the Phase
I/II trial for HM is a first in man safety and efficacy study, for this
stage, NiCord was transplanted with a second un-manipulated cord blood
unit in a double cord blood configuration.